Gland Pharma — Q2 FY27 — November 6, 2026

1. Overall Tone of Management

Optimistic, supported by 23% year-on-year revenue growth, sharply higher EBITDA and PAT, strong US and CDMO performance, and repeated confidence in the growth outlook. The optimism is not without caveats: Cenexi recorded a €6 million EBITDA loss, ROW was affected by tender delays, working-capital days increased, and management gave limited visibility on currency effects and GLP-1 revenues. Its reaffirmation of Cenexi’s prior-year-end targets despite a weak quarter also deserves scrutiny.

2. Key Themes from Management Commentary

CDMO is becoming a larger growth and earnings driver. Q2 CDMO revenue rose 31% to ₹8,227 million and represented approximately 45% of group revenue. Management said the pipeline is stronger in both quality and scale, but several complex projects have long development and commercialization timelines.
Strong US performance, with some geographic unevenness. US revenue increased 42%, supported by launches, existing-product volumes and CDMO programs. Europe grew 23%; ROW revenue was affected by delayed Nupco tender results.
Capacity constraints are prompting a larger investment program. Management said utilization is high in selected product lines and that it is not taking planned shutdowns on some lines because it cannot risk missing orders. It announced an additional ₹1,000 crore brownfield project alongside its previously announced ₹2,000 crore program; a separate Vizag greenfield plan is still being developed.
Cenexi remains a turnaround story, not yet a consistent earnings contributor. The €6 million Q2 loss was attributed to planned shutdowns. Management expects profitability from Q3, while emphasizing cost reduction and efficiency over revenue growth.
Investment in complex products and China-linked opportunities is increasing. R&D was 6% of Q2 revenue; management also described China in-licensing, Indian-market launches of innovative products, and a global acquisition role based in China.
Quality and compliance were highlighted as differentiators. Vizag oncology cleared a US FDA inspection with zero observations; Dundigal had four procedural observations, which management said were neither data-integrity nor repeat observations.

3. Q&A Analysis

Growth outlook, US momentum and ROW

Questions: Can H1’s 21% growth continue for the full year? Is US growth repeatable, and can ROW recover?
Management: Reiterated full-year growth guidance of 15% on a constant-currency basis; said US growth was driven by launches and new CDMO business, “there is no bulkiness,” and expects ROW to improve.
Assessment: The US answer was unusually direct. By contrast, management said constant-currency growth is difficult to quantify and gave no specific ROW target. The 15% full-year outlook is a step up from the 12–13% constant-currency consolidated outlook stated in Q4 FY26, a notable change in guidance framing.

Capacity expansion and capital discipline

Questions: How much capex is planned, how much capacity will it add, and is investment backed by firm customer demand or softer forecasts?
Management: Confirmed the previously announced ₹2,000 crore program and described a further ₹1,000 crore brownfield project for three isolator-based vial lines at Pashamylaram. The ₹3,000 crore brownfield total is expected to add 300–400 million units. Vizag greenfield capex remains unquantified; management said it may disclose more next quarter. It cited contracts, customer forecasts and high utilization as the basis for the brownfield spend, while saying greenfield investment will be phased.
Assessment: Management gave useful utilization and capacity figures, but did not quantify take-or-pay or customer co-funding coverage. The greenfield project’s total cost and returns remain undisclosed.

Cenexi performance and FY27 targets

Questions: How should investors view Cenexi’s growth and profitability after a shutdown-related loss? Does earlier FY27 guidance still hold?
Management: Attributed the €6 million EBITDA loss to planned annual shutdowns and said profitability is expected from Q3. It reaffirmed the earlier FY27 estimate when challenged on the implied H2 recovery, saying the quarter’s lower number had been anticipated.
Assessment: This was the most consequentially optimistic answer. Management did not provide a revised forecast or explain the bridge to the target in detail. The Q&A exchange itself included an analyst’s calculation implying a steep H2 recovery; management’s response was essentially that the target remains “on track.”

CDMO contracts, microspheres and future launches

Questions: What is the size and timing of the microsphere contracts, and what can sustain US growth?
Management: Said three microsphere projects had been signed, with initial development/tech-transfer revenue and royalty-based commercial revenue expected after FY29–FY30. For US growth, it cited annualization of recent launches, Micafungin approval and future CDMO launches, including GLP-1 projects.
Assessment: Management offered timing and product examples but no contract value or revenue range for microspheres. It also declined to quantify GLP-1 revenue.

China in-licensing, India strategy and M&A

Questions: What is the purpose of appointing a China-based CIO, and are Chinese products intended for Indian or global markets?
Management: Described the role as global—covering acquisitions, complex-product and technology in-licensing—with a possible US biologics acquisition among the objectives. The India-focused in-licensing strategy is primarily to bring innovative products to the Indian market rather than compete in commoditized generics. It also disclosed two long-acting injectable products: one with an approximately $800 million market and another, still patented, with an approximately $2 billion market and a three-year timeline.
Assessment: This was relatively specific about strategic intent, but not about deal economics, licensing terms or expected revenue.

Margins, R&D, currency and segment economics

Questions: What drove the gross-margin decline sequentially? How should investors interpret R&D spending and CDMO margins? What was constant-currency growth?
Management: Attributed lower gross margin versus Q1 to Cenexi’s shutdown-related lower revenue; said CDMO margins are probably 5–10% higher than the company’s own injectable business. It expects R&D to rise slightly over time while maintaining current margin levels. It declined to provide an exact constant-currency growth figure.
Assessment: Segment margin disclosure was unusually helpful. The currency answer was partial, and the commitment to preserve margins while R&D increases was not accompanied by a quantified margin outlook.

4. Guidance / Outlook

Quantitative guidance

Consolidated revenue: Full-year growth guidance reiterated at 15% constant currency. This differs from the 12–13% constant-currency outlook cited in Q4 FY26.
Cenexi: Earlier FY27 guidance was reaffirmed; management expects profitability from Q3 and did not revise the previous full-year estimate. The prior call’s target, as discussed by analysts, was around €200 million revenue and high-single-digit EBITDA margin.
Capex and capacity: Previously announced ₹2,000 crore expansion remains on track. An additional ₹1,000 crore brownfield project was announced; the brownfield spend of approximately ₹3,000 crore is expected to add 300–400 million units. Pashamylaram commercial operations are anticipated from FY30. Vizag greenfield capex has not been disclosed.
R&D: Q2 spend was ₹1,074 million, or 6% of revenue; management expects a modest increase over time but said it aims to maintain current margin levels.

Qualitative signals

US momentum is expected to continue, with management saying Q2 growth was not unusually lumpy.
Management expects ROW to improve, though it did not quantify the recovery.
CDMO is expected to grow faster than the critical-injectables business.
Cenexi profitability is expected to resume from Q3, with efficiency and cost reduction prioritized over topline growth.
GLP-1 projects may generate tech-transfer and milestone income, with some launches potentially in Q1 or Q2 next year; management provided no GLP-1 revenue guidance.
A board decision on the additional Vizag greenfield capex is expected in a coming quarter.

5. Standout Statements

“Our guidance for full-year growth remains the same at 15% on a constant-currency basis.”
“This should continue; there is no bulkiness,” referring to US growth.
“We are struggling for capacity” in ophthalmics, bags and liquid vials; management said some planned shutdowns were being avoided to protect supply.
“The focus is on making it more efficient and more profitable rather than on the topline,” on Cenexi.
Management said Cenexi plans to reduce employee numbers and install faster lines to improve operating efficiency.
The new brownfield project reflects the extent of capacity pressure: liquid-vial utilization was described at 82%, with management anticipating 91–92% next year.
The 15% full-year growth guidance is more assertive than the 12–13% constant-currency consolidated outlook given in Q4 FY26.

6. Red Flags / Positive Signals

Red flags
– Cenexi’s €6 million EBITDA loss reverses the positive EBITDA performance reported in Q3 and Q4 FY26; the expected recovery is concentrated in H2.
– The reaffirmed Cenexi target was not supported with a detailed recovery bridge.
– ROW remains exposed to tender timing; Nupco results were delayed.
– Working-capital days increased to 168 from 164 at FY26 year-end.
– Expansion capex is accelerating, while the greenfield project’s cost and returns have not been disclosed.
– Management would not quantify constant-currency growth, GLP-1 exposure or capacity contracted against customer forecasts.

Positive signals
– Revenue, EBITDA and PAT grew 23%, 63% and 58%, respectively, year on year.
– CDMO growth of 31% and 45% revenue contribution reinforce a substantial shift in business mix.
– US revenue grew 42%, and management explicitly said the growth was not driven by a one-off or bulkiness.
– Net cash was approximately ₹32.2 billion, supporting the planned investment program.
– The Vizag oncology facility received a zero-observation US FDA inspection.

7. Historical Comparison & Consistency Analysis

a. Quarter-by-Quarter Tone Evolution

Q2 FY26 — November 3, 2025

Dominant tone: Optimistic
Major themes this quarter:
Core-business growth was modest: consolidated revenue grew 6%, with US and Europe growth offset by weak ROW CMO activity.
Management expected a stronger second half, supported by launches, volume growth, CDMO and Cenexi.
The strategy emphasized complex injectables, GLP-1, biologics, R&D and margin efficiency.
Cenexi’s turnaround was framed around cost actions, price increases and capacity improvements.
Tone shift vs previous quarter: N/A (baseline)
What changed: N/A (baseline)

Q3 FY26 — January 28, 2026

Dominant tone: Optimistic
Major themes this quarter:
Revenue growth accelerated to 22% and adjusted EBITDA rose 25%.
Cenexi reached positive quarterly EBITDA, supporting the turnaround narrative.
GPO contracts, product launches and CDMO activity were presented as growth drivers.
The ₹2,000 crore capacity program and 140-million-unit cartridge capacity featured prominently.
Tone shift vs previous quarter: More Optimistic
What changed:
Confidence was supported by a sharp improvement in reported growth from Q2’s 6%.
Management reported Cenexi’s first positive EBITDA quarter and described the turnaround as gaining momentum.
It maintained ambitious expectations, including mid-teens growth over time, while acknowledging GLP-1 ramp-up would take time.

Q4 FY26 — May 15, 2026

Dominant tone: Optimistic
Major themes this quarter:
Record quarterly revenue and EBITDA, with FY26 revenue growth of 14.5%.
CDMO represented 46% of group revenue; Dalbavancin and other launches supported momentum.
Cenexi was described as EBITDA-positive and operationally stable.
Management gave FY27 growth expectations of around 12–13% constant currency and set out a ₹2,000 crore capacity plan.
Tone shift vs previous quarter: More Optimistic
What changed:
Full-year results and record Q4 performance strengthened confidence versus Q3.
Cenexi’s recovery narrative moved from quarterly breakeven to profitability and a mid-term mid-teens EBITDA objective.
Near-term consolidated growth expectations were more restrained than the broad mid-teens longer-term aspiration.

Q2 FY27 — November 6, 2026

Dominant tone: Optimistic
Major themes this quarter:
Strong group growth, especially in the US and CDMO.
Capacity constraints prompted a further brownfield project and plans for a Vizag greenfield site.
Cenexi’s shutdown-related loss was positioned as temporary, with profitability expected from Q3.
China-linked product licensing and investment opportunities received greater emphasis.
Tone shift vs previous quarter: More Optimistic overall, but with greater execution risk
What changed:
Guidance increased from the prior call’s 12–13% consolidated constant-currency outlook to 15%.
Capacity investment expanded beyond the previously announced ₹2,000 crore program.
Cenexi shifted from positive EBITDA in Q4 FY26 to a loss, but management maintained the turnaround outlook.

Trajectory Summary: Management’s confidence rose as growth strengthened from Q2 to Q4 FY26, then remained high in Q2 FY27 despite a sharp, shutdown-related Cenexi setback. The narrative has shifted from recovering growth and proving the Cenexi turnaround toward capacity scarcity and faster CDMO expansion; the higher current growth guidance and enlarged capex plan raise the execution stakes.

b. Tracking Past Commitments vs Outcomes

FY26 “mid-teens” consolidated growth expectation — Q2 FY26: Management said it expected to come close to the target. FY26 revenue growth was 14.5% reported. ✅ Delivered approximately, though constant-currency growth was not supplied here.
Cenexi Q3 FY26 breakeven at approximately €50 million revenue — Q2 FY26/Q3 FY26 calls: Q3 FY26 revenue was €50 million and EBITDA €1.4 million. ✅ Delivered.
Cenexi FY27 revenue near €200 million and high-single-digit EBITDA — Q4 FY26: Q2 FY27’s quarter produced €41 million revenue and a €6 million EBITDA loss, which management attributed to the planned shutdown; it reaffirmed the earlier estimate and expects profitability from Q3. ⏳ In progress / at risk; the year-end target is not yet due, but the required H2 recovery is significant.
₹2,000 crore capacity program — Q2/Q3 FY26 and Q4 FY26: Still being executed; management now describes an additional ₹1,000 crore brownfield expansion, while the greenfield project remains at planning stage. ⏳ In progress.
Large CDMO project expected to commercialize in H2 FY28, with $25–30 million annual revenue potential — Q3/Q4 FY26: The current call did not specifically update that project. Not yet due; not specifically updated.
GLP-1 capacity ramp — Q3 FY26: Earlier management expected 15–20 million units of FY27 utilization and said GLP-1 guidance excluded potential upside. Current management still withholds revenue guidance and expects some tech-transfer/milestone revenue, with launches potentially in FY28. ⏳ Commercial ramp remains uncertain; no clear utilization outcome disclosed.

c. Narrative Shifts

From capacity-building to capacity shortages: Earlier calls described planned investment to support expected demand; management now says existing lines are constrained and some shutdowns are being deferred.
Cenexi emphasis has moved from turnaround progress to cost discipline. After positive EBITDA in Q3 and Q4 FY26, the current call prioritizes efficiency and headcount reduction over revenue growth.
China is a more visible strategic priority: The current call adds China-based business development, product in-licensing into India and a global CIO/M&A role.
GLP-1 remains strategically prominent but financially unquantified. Capacity and contracts have been discussed for several calls, yet management continues to exclude GLP-1 from guidance.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management has been reasonably consistent about the long CDMO commercialization cycle, the uncertain GLP-1 ramp and Cenexi’s need for operational improvement. It also acknowledged the planned-shutdown loss and disclosed specific capacity constraints. However, Cenexi recovery targets have been repeatedly reaffirmed despite volatile results, and the current 15% constant-currency guidance is higher than the 12–13% consolidated outlook in Q4 FY26 without a detailed bridge. Currency and customer-commitment questions also remained only partially answered.

e. Evolution of Key Themes

Demand and growth — Improving: Revenue growth accelerated from 6% in Q2 FY26 to 22% in Q3 and 23% in current Q2 FY27. ROW remains uneven.
Margins — Improving overall, but volatile at Cenexi: Consolidated profitability improved materially; Cenexi’s Q2 FY27 loss interrupts its prior positive-quarter trend.
CDMO — Improving: Revenue contribution and growth have increased, with a broader pipeline and additional capacity commitments. Some large projects remain several years from commercialization.
Cenexi turnaround — Stable but fragile: Earlier progress was real, but the current shutdown loss and H2 recovery requirement show the earnings path is not yet smooth.
Capital intensity — Increasing: The original ₹2,000 crore plan is now accompanied by a further ₹1,000 crore brownfield project and a still-unpriced greenfield project.
GLP-1 — Stable strategic opportunity, uncertain near-term economics: Capacity and partnerships have advanced, but management remains unwilling to forecast meaningful contribution.

f. Additional Insights

The stronger growth outlook and expanded capacity spend are linked: management’s rationale is not just projected demand but stated current bottlenecks and contracts that require capacity before commercialization.
The company is becoming more CDMO-led, which management says improves visibility and margins, but the new-project pipeline also creates a longer lag between investment and revenue.
Cenexi’s role is increasingly framed as a cost and capability platform rather than a near-term topline engine; the Q2 shutdown loss makes proof of the promised operating leverage important.

Gland Pharma Raises FY27 Growth Outlook to 15%